Document Detail


Oral paricalcitol (19-nor-1,25-dihydroxyvitamin D2) in women receiving chemotherapy for metastatic breast cancer: a feasibility trial.
MedLine Citation:
PMID:  23760489     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The vitamin D hormone, [1,25(OH) 2D, calcitriol], inhibits proliferation and angiogenesis in breast cancer but its therapeutic use is limited by hypercalcemia. Synthetic analogs of 1,25(OH) 2D that are less calcemic, such as paricalcitol (19-nor-1,25-Dihydroxyvitamin D 2), are used to treat hyperparathyroidism associated with chronic kidney disease. We sought to determine the safety and feasibility of taking oral paricalcitol with taxane-based chemotherapy in women with metastatic breast cancer (MBC). Oral paricalcitol was considered safe if it did not result in excessive toxicity, defined as grade 3 or higher serum calcium levels. It was considered feasible if the majority of women could take eight weeks of continuous therapy in the first three months. Serum calcium was monitored weekly and the paricalcitol dose was adjusted based on its calcemic effect. Intact parathyroid hormone (iPTH) was monitored as a marker of paricalcitol activity. Twenty-four women with MBC were enrolled. Twenty women (83%) received eight weeks of continuous therapy. Paricalcitol was well-tolerated with no instances of hypercalcemia grade 2 or greater. Fourteen women (54%) were able to escalate the dose. The dose range of paricalcitol in the first 3 mo was 2-7 ug/day. Serum iPTH levels at baseline were significantly higher in women with serum 25-Hydroxyvitamin D (25-OHD) levels less than 30 ng/ml (96.4 ± 40.9 pg/ml) vs. 46.2 ± 20.3 pg/ml (p = 0 0.001) (iPTH reference 12-72 pg/ml). We conclude that paricalcitol is safe and feasible in women with MBC who are receiving chemotherapy.
Authors:
Julia A Lawrence; Steven A Akman; Susan A Melin; L Douglas Case; Gary G Schwartz
Related Documents :
20391009 - Authoritarian and homophobic attitudes: gender and adult attachment style differences.
19294319 - Gender adjustment or stratification in discerning upper extremity musculoskeletal disor...
17963099 - Global rights, local realities: negotiating gender equality and sexual rights in the ca...
23750489 - Risk of oral anti-fungal agent-induced liver injury in taiwanese.
18314789 - In times of uncertainty: predicting the survival of long-distance relationships.
20607899 - Grand dames and gentle helpmeets: women and the royal honours system in new zealand, 19...
12580389 - Factors affecting adolescent reproductive health in manitoba.
8950499 - The pharmacology and effectiveness of specific lipid-active drugs: estrogen/sex steroids.
21785119 - Ciprofloxacin safety in paediatrics: a systematic review.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Cancer biology & therapy     Volume:  14     ISSN:  1555-8576     ISO Abbreviation:  Cancer Biol. Ther.     Publication Date:  2013 Jun 
Date Detail:
Created Date:  2013-06-13     Completed Date:  2014-01-14     Revised Date:  2014-06-03    
Medline Journal Info:
Nlm Unique ID:  101137842     Medline TA:  Cancer Biol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  476-80     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  pharmacology,  therapeutic use*
Breast Neoplasms / drug therapy*,  pathology
Dose-Response Relationship, Drug
Ergocalciferols / administration & dosage
Feasibility Studies
Female
Humans
Hypercalcemia / chemically induced
Lymphatic Metastasis
Middle Aged
Taxoids / administration & dosage
Treatment Outcome
Grant Support
ID/Acronym/Agency:
P30 CA012197/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Ergocalciferols; 0/Taxoids; 131918-61-1/paricalcitol
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lun...
Next Document:  Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acq...